SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurobiological Tech (NTII)
An SI Board Since September 1996
Posts SubjectMarks Bans Symbol
1494 40 0 NTII
Emcee:  Miles Rhyne Hoffman, CFA Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
794 <<galantamine is for symptomatic relief ...>> <<Memantine on John McCarthy-3/3/2000
793 John, thanks for bringing this forward. galantamine is for symptomatic relief. Dr. John M. de Castro-3/3/2000
792 Dr. John ...... Any perspective on this ........ biz.yahoo.com regards, JohnJohn McCarthy-3/3/2000
791 Here is a link to a relatively old (1996) but still excellent article on AIDS DDr. John M. de Castro-3/2/2000
790 Another demonstration of NMDA antagonist's utility for the treatment of neuDr. John M. de Castro-2/28/2000
789 Off-Label Usage ............ John - thanks .... I wondered about this but didnJohn McCarthy-2/26/2000
788 Good point, John. The medscape article statement, "Unlike some NMDA antagCheryl Galt-2/26/2000
787 Thanks Cheryl! I just want to make one clarification. The article states "Dr. John M. de Castro-2/26/2000
786 A Reuters Medical News summary of the vaccine article is in Medscape today. medCheryl Galt-2/26/2000
785 Interesting article in this weeks Science. The technique may one day obviate thDr. John M. de Castro-2/25/2000
784 Neurobiological Technologies, Inc. Announces Positive Results from Phase III TrDr. John M. de Castro-2/22/2000
783 John, I just want to personally thank you for the excellent post and for your lJMarcus-2/21/2000
782 Valuing a biotech stock is difficult because you not only have to look at the fDr. John M. de Castro-2/20/2000
781 John, I've been long NTII for a couple of years now and attended the last tJMarcus-2/20/2000
780 What is the most common complication of diabetes mellitus? A: The most commonDr. John M. de Castro-2/18/2000
779 HIV-Associated Dementia and Cognitive Impairment - Neuroprotective Effects of ADr. John M. de Castro-2/18/2000
778 Expert Commentary on: Diabetic Polyneuropathy From a public health perspectiveDr. John M. de Castro-2/18/2000
777 Neurobiological Technologies, Inc. Announces Second Quarter Results biz.yahoo.sim1-2/14/2000
776 fyi ........ institutional holdings ...... insidertrader.com I expect this wiJohn McCarthy-2/13/2000
775 Dr. John M. <<The neurotoxicity caused by Tat and gp120 applied in combiJohn McCarthy-2/12/2000
774 Attached is the abstract of a very nice study demonstrating one of the ways thaDr. John M. de Castro-2/11/2000
773 >>>BTW: Congratulations to Dr. DeCastro and the others on this thread John Wright-2/10/2000
772 John, thanks for the interesting links. Almost half the buying by institutions.Craig S. Owens-2/9/2000
771 Lots of Green Lines today ............ stockpoint.com Please don't jump John McCarthy-2/9/2000
770 Dr. John, This is very encouraging. My birthday comes up May 15th. I hope my prCraig S. Owens-2/9/2000
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News